Should a Struggling Medtech Company Get a Second Chance: Interview With IONIQ CEO Jared Bauer
October 28, 2021
IONIQ CEO, Jared Bauer – a self-described “heavy thinker” was featured in a recent episode of Medsider.
Bauer explains the two key factors he looks at when determining whether a medical device company is worth trying to turn around, why finding investors who really care about your mission is a strategic benefit, and why he hopes that IONIQ’s devices will one day have a place in your medicine cabinet.
IONIQ Sciences, using bioimpedance, is developing a device that can potentially detect cancers in early stages. The company’s device was granted a breakthrough designation for lung cancer by the FDA in 2020.
Recent News
- bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
- DGENTHERA AND NUSANO SIGN LETTER OF INTENT FOR ASTATINE‑211 SUPPLY
- 2025 BIO International Recap
- Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation
- Nelson Labs to Double Cleanroom Capacity to Support Growing Demand for Sterility Assurance Services
- RATIO THERAPEUTICS AND NUSANO ENTER LONG-TERM, MULTI-ISOTOPE SUPPLY AGREEMENT TO BOOST PRODUCTION OF CANCER RADIOPHARMACEUTICALS
